<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7102570\results\search\disease\results.xml">
  <result pre="stockpiled for 2 million people as a countermeasure for novel" exact="influenza" post="strains. This drug functions as a chain terminator at"/>
  <result pre="the viral load. Favipiravir cures all mice in a lethal" exact="influenza" post="infection model, while oseltamivir fails to cure the animals."/>
  <result pre="life-threatening Ebola virus, Lassa virus, rabies, and severe fever with" exact="thrombocytopenia" post="syndrome. The best feature of favipiravir as an antiviral"/>
  <result pre="efficacy from the first to the last patient in an" exact="influenza" post="pandemic or an epidemic lethal RNA virus infection. Favipiravir"/>
  <result pre="an important therapeutic agent for severe influenza, the next pandemic" exact="influenza" post="strain, and other severe RNA virus infections for which"/>
  <result pre="RdRp, RNA-dependent RNA polymerase RTP, 4-ribofuranosyl-5′-triphosphate SFTS, severe fever with" exact="thrombocytopenia" post="syndrome 1 Introduction Acyclovir enabled the first systemic antiviral"/>
  <result pre="and many antiviral agents have subsequently been developed. Acyclovir targets" exact="herpes simplex" post="virus and varicella-zoster infection, and individual antiviral agents target"/>
  <result pre="(T-705) is its broad spectrum activity toward RNA viruses, including" exact="influenza" post="virus, rhinovirus, and respiratory syncytial virus, but not DNA"/>
  <result pre="Furuta et al., 2009). Favipiravir shows better efficacy in treating" exact="influenza" post="infections than oseltamivir (Tamiflu) (Takahashi et al., 2003; Tanaka"/>
  <result pre="Tanaka et al., 2017), and its efficacy in treating pathogenic" exact="avian influenza" post="A(H5N1) and oseltamivir-resistant viruses has been confirmed in animals"/>
  <result pre="et al., 2017), and its efficacy in treating pathogenic avian" exact="influenza" post="A(H5N1) and oseltamivir-resistant viruses has been confirmed in animals"/>
  <result pre="marked by red circles. Clinical trials of treatments for seasonal" exact="influenza" post="have been performed in Japan and US, and favipiravir"/>
  <result pre="favipiravir was approved as a treatment for novel or re-emerging" exact="influenza" post="viruses in Japan in 2014. Favipiravir is considered for"/>
  <result pre="will be used as a countermeasure against novel or re-emerging" exact="influenza" post="viruses. The Japanese government and Taiwanese Centers for Disease"/>
  <result pre="has been submitted for additional indications for severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) based on clinical trials (Yasukawa, 2016) in"/>
  <result pre="(SFTS) based on clinical trials (Yasukawa, 2016) in addition to" exact="influenza" post="in Japan. Favipiravir was highlighted as a treatment during"/>
  <result pre="al., 2014; Smither et al., 2014) and is licensed for" exact="influenza" post="treatment based on its confirmed safety and efficacy in"/>
  <result pre="al., 2015; Sissoko et al., 2016). Since children died of" exact="avian influenza" post="A(H5N1) in Hong Kong in 1997 (Ku &amp;amp; Chan,"/>
  <result pre="2015; Sissoko et al., 2016). Since children died of avian" exact="influenza" post="A(H5N1) in Hong Kong in 1997 (Ku &amp;amp; Chan,"/>
  <result pre="Kong in 1997 (Ku &amp;amp; Chan, 1999), concern regarding novel" exact="influenza" post="pandemics, such as A(H5N1) and A(H7N9), has been noted"/>
  <result pre="noted because no one is immune to these viruses. Novel" exact="influenza" post="strains cause more severe diseases, particularly pneumonia, than seasonal"/>
  <result pre="seasonal influenza, and the mortality rate is 53.5% (483/903) for" exact="influenza" post="A(H5N1) (Lai et al., 2016) and 34% (47/137) for"/>
  <result pre="influenza A(H5N1) (Lai et al., 2016) and 34% (47/137) for" exact="influenza" post="A(H7N9) (Li et al., 2014). A combination therapy with"/>
  <result pre="with oseltamivir has been used to treat patients with severe" exact="influenza" post="in China (Cao, 2018; Wang et al., 2019). Although"/>
  <result pre="China (Cao, 2018; Wang et al., 2019). Although each novel" exact="influenza" post="strain currently occurs sporadically, researchers are concerned about the"/>
  <result pre="to play a central role in the treatment of lethal" exact="influenza" post="pandemic and other severe RNA virus infections for which"/>
  <result pre="scientists, and policy-makers who are considering preparedness strategies for new" exact="influenza" post="pandemics and prevention through vaccine development. 2 Development as"/>
  <result pre="resistant viruses was investigated. Clinical trials of treatments for seasonal" exact="influenza" post="have been performed in Japan and the US, and"/>
  <result pre="favipiravir was approved as a treatment for novel or re-emerging" exact="influenza" post="viruses in Japan in 2014. However, favipiravir (Avigan®) is"/>
  <result pre="will be used as a countermeasure for novel or re-emerging" exact="influenza" post="viruses. In addition, favipiravir is contraindicated for use in"/>
  <result pre="Japanese government decided to stockpile favipiravir (Avigan®) as a novel" exact="influenza" post="countermeasure for 2 million people in 2017. Recent clinical"/>
  <result pre="a combination therapy with oseltamivir to treat patients with severe" exact="influenza" post="in China (Cao, 2018; Wang et al., 2019). In"/>
  <result pre="Favipiravir showed anti-influenza virus activity toward all subtypes of seasonal" exact="influenza" post="virus strains, including types A, B and C of"/>
  <result pre="0.55 μg/mL (Furuta et al., 2002). Although the effectiveness against" exact="influenza" post="viruses at the cell culture level was confirmed, the"/>
  <result pre="was confirmed by analyzing its efficacy in animal models of" exact="influenza" post="infection, as described below, which led to drug development."/>
  <result pre="and respiratory syncytial virus but not effective against DNA viruses," exact="herpes simplex" post="virus-1, cytomegalovirus, and adenovirus (Furuta et al., 2002). Based"/>
  <result pre="bCDC, cPan American Health Organization (PAHO) &amp;amp; WHO, dWestern equine" exact="encephalitis" post="(Spickler, 2017), eArgentine hemorrhagic fever virus infection (Enria &amp;amp;"/>
  <result pre="Influenza infection model We have identified two antipyretic steps in" exact="influenza" post="infections, as shown in Fig. 2 . Influenza infection"/>
  <result pre="the bronchoalveolar fluids of mice and decrease the area of" exact="pneumonia" post="throughout the lungs. The role of IL-12 on day"/>
  <result pre="by cinnamyl compounds and NSAIDs in the fever cascade in" exact="influenza" post="infection. Fig. 2 Cascade of fever induction by influenza"/>
  <result pre="in influenza infection. Fig. 2 Cascade of fever induction by" exact="influenza" post="and antipyretic action of cinnamyl compounds and NSAIDs. Influenza"/>
  <result pre="the viral load in the BALF and the area of" exact="pneumonia" post="throughout the lungs. Studies of the efficacy of favipiravir"/>
  <result pre="throughout the lungs. Studies of the efficacy of favipiravir on" exact="influenza" post="in animals have been performed in our biosafety level"/>
  <result pre="of favipiravir were conducted in mice and ferrets using the" exact="influenza" post="infection system described above in our laboratory. 2.4 Efficacy"/>
  <result pre="favipiravir in influenza-infected animals Since our laboratory had established an" exact="influenza" post="infection model to investigate the cytokine cascade that induces"/>
  <result pre="model to investigate the cytokine cascade that induces fever in" exact="influenza" post="virus-infected animals, we performed a virological analysis by examining"/>
  <result pre="Shiraki, 1998; Tsurita et al., 2001). Our animal model for" exact="influenza" post="was used to study the efficacy of favipiravir in"/>
  <result pre="effective in cell culture, its effectiveness in animals infected with" exact="influenza" post="virus must be confirmed. We first observed the prevention"/>
  <result pre="be confirmed. We first observed the prevention of a lethal" exact="influenza" post="infection. Oral administration of favipiravir was significantly effective in"/>
  <result pre="infection. Oral administration of favipiravir was significantly effective in alleviating" exact="influenza" post="infection in mice (Furuta et al., 2002), and its"/>
  <result pre="We are convinced that favipiravir will be developed as an" exact="influenza" post="drug for humans after the confirmation of its therapeutic"/>
  <result pre="in two species of animals, mice and ferrets, infected with" exact="influenza" post="virus. Fig. 3 shows one of the comparisons of"/>
  <result pre="the comparisons of efficacy between favipiravir and oseltamivir in the" exact="influenza" post="virus infection model established with a high titer of"/>
  <result pre="oseltamivir was observed in an animal with a severe lethal" exact="influenza" post="infection with a high viral load (Takahashi et al.,"/>
  <result pre="in low-dose infections, but the efficacy of favipiravir as an" exact="influenza" post="drug is clearly increased compared with oseltamivir in high-titer"/>
  <result pre="1, 24, 48, or 72 h after infection with seasonal" exact="influenza" post="A(H1N1) (Takahashi et al., 2003). Fig. 3 Comparison of"/>
  <result pre="Comparison of the efficacy of favipiravir and oseltamivir in lethal" exact="influenza" post="virus infection. Mice were infected with 3 × 104"/>
  <result pre="were infected with 3 × 104 plaque forming units of" exact="influenza" post="A/PR/8/34 virus and were orally administered favipiravir and oseltamivir"/>
  <result pre="infection model and is considered to correspond to a novel" exact="influenza" post="infection in humans. Although oseltamivir is ineffective in this"/>
  <result pre="recognition of the single-strand RNA or double-strand RNA of the" exact="influenza" post="virus genome by Toll-like receptor-7/8 (Yang &amp;amp; Chen, 2012)"/>
  <result pre="cell-based system. Favipiravir significantly suppresses the production of TNF-α in" exact="influenza" post="virus-infected P388D1 cells compared with the active form of"/>
  <result pre="pulmonary viral load and TNF-α level in the airways of" exact="influenza" post="virus-infected mice compared with oseltamivir, and the reduction in"/>
  <result pre="contribute to the enhanced effects of favipiravir treatment on alleviating" exact="influenza" post="infection compared with oseltamivir treatment. Favipiravir displays superior properties"/>
  <result pre="its possible use as the standard treatment of choice for" exact="influenza" post="in the future. 3 Mechanisms of action of current"/>
  <result pre="of action of current anti-influenza drugs Fig. 4 shows the" exact="influenza" post="virus growth cycle and the sites of action of"/>
  <result pre="the next round of infection. Fig. 4 Replication cycle of" exact="influenza" post="and sites of action of anti-influenza drugs. Influenza virus"/>
  <result pre="rich source of resistant viruses. Amantadine inhibits the uncoating of" exact="influenza" post="A in late endosomes, and viral RNA does not"/>
  <result pre="does not replicate in the infected cells. Amantadine inhibits only" exact="influenza" post="A and not B. However, influenza A virus becomes"/>
  <result pre="cells. Amantadine inhibits only influenza A and not B. However," exact="influenza" post="A virus becomes resistant, even in an epidemic occurring"/>
  <result pre="an epidemic occurring in a closed facility, and the current" exact="influenza" post="A viruses are not susceptible to amantadine. Favipiravir inhibits"/>
  <result pre="drugs. Baloxavir marboxil (baloxavir, Xofluza®) is a selective inhibitor of" exact="influenza" post="Cap-dependent endonuclease of the viral RdRp complex. Baloxavir inhibits"/>
  <result pre="baloxavir. 3.2 A reservoir of resistant virus is generated in" exact="influenza" post="virus-infected cells treated with anti-influenza drugs other than favipiravir"/>
  <result pre="source of drug-resistant viruses. The spontaneous mutation rate of the" exact="influenza" post="virus RdRp complex is approximately 1 × 104. Titers"/>
  <result pre="virus RdRp complex is approximately 1 × 104. Titers of" exact="influenza" post="virus in culture reach approximately 108 plaque forming units/mL"/>
  <result pre="drugs serves as a source of drug-resistant viruses. Subsequently, drug-resistant" exact="influenza" post="viruses should appear more readily from the mutant genomic"/>
  <result pre="the mutant genomic RNA pool during drug treatment. 4 Seasonal" exact="influenza" post="and pandemic influenza 4.1 Seasonal influenza The replication cycle"/>
  <result pre="RNA pool during drug treatment. 4 Seasonal influenza and pandemic" exact="influenza" post="4.1 Seasonal influenza The replication cycle of influenza viruses"/>
  <result pre="drug treatment. 4 Seasonal influenza and pandemic influenza 4.1 Seasonal" exact="influenza" post="The replication cycle of influenza viruses is approximately 6"/>
  <result pre="and pandemic influenza 4.1 Seasonal influenza The replication cycle of" exact="influenza" post="viruses is approximately 6 h from entry to the"/>
  <result pre="rate of four replication cycles per day. The course of" exact="influenza" post="virus infection was analyzed in 56 different studies with"/>
  <result pre="56 different studies with 1280 healthy participants after an experimental" exact="influenza" post="virus infection (Carrat et al., 2008). The A(H1N1) and"/>
  <result pre="increase in viral shedding on the first day after experimental" exact="influenza" post="virus infection, and they reached their maximum values on"/>
  <result pre="modifying the severity of symptoms of influenza. 4.2 Difference in" exact="influenza" post="pathogenesis between seasonal and novel influenza Seasonal influenza strains"/>
  <result pre="influenza. 4.2 Difference in influenza pathogenesis between seasonal and novel" exact="influenza" post="Seasonal influenza strains that are adapted to humans include"/>
  <result pre="Difference in influenza pathogenesis between seasonal and novel influenza Seasonal" exact="influenza" post="strains that are adapted to humans include A(H1N1), A(H3N2),"/>
  <result pre="that are adapted to humans include A(H1N1), A(H3N2), and B" exact="influenza" post="and cause seasonal epidemics of influenza among humans every"/>
  <result pre="A(H1N1), A(H3N2), and B influenza and cause seasonal epidemics of" exact="influenza" post="among humans every year. Seasonal influenza viruses mainly infect"/>
  <result pre="cause seasonal epidemics of influenza among humans every year. Seasonal" exact="influenza" post="viruses mainly infect the epithelium of the upper respiratory"/>
  <result pre="degree of immunity of the host as described above. Novel" exact="influenza" post="is derived from avian influenza A and is a"/>
  <result pre="the host as described above. Novel influenza is derived from" exact="avian influenza" post="A and is a source of concern as a"/>
  <result pre="host as described above. Novel influenza is derived from avian" exact="influenza" post="A and is a source of concern as a"/>
  <result pre="is a source of concern as a cause of an" exact="influenza" post="pandemic. Avian influenza is divided into highly pathogenic avian"/>
  <result pre="of concern as a cause of an influenza pandemic. Avian" exact="influenza" post="is divided into highly pathogenic avian influenza and low-pathogenic"/>
  <result pre="an influenza pandemic. Avian influenza is divided into highly pathogenic" exact="avian influenza" post="and low-pathogenic avian influenza based on the molecular characteristics"/>
  <result pre="influenza pandemic. Avian influenza is divided into highly pathogenic avian" exact="influenza" post="and low-pathogenic avian influenza based on the molecular characteristics"/>
  <result pre="influenza is divided into highly pathogenic avian influenza and low-pathogenic" exact="avian influenza" post="based on the molecular characteristics of the virus and"/>
  <result pre="is divided into highly pathogenic avian influenza and low-pathogenic avian" exact="influenza" post="based on the molecular characteristics of the virus and"/>
  <result pre="abilities to cause disease and mortality in chickens. Both low-pathogenic" exact="avian influenza" post="and highly pathogenic avian influenza viruses have caused severe"/>
  <result pre="to cause disease and mortality in chickens. Both low-pathogenic avian" exact="influenza" post="and highly pathogenic avian influenza viruses have caused severe"/>
  <result pre="mortality in chickens. Both low-pathogenic avian influenza and highly pathogenic" exact="avian influenza" post="viruses have caused severe and lethal infections in humans"/>
  <result pre="in chickens. Both low-pathogenic avian influenza and highly pathogenic avian" exact="influenza" post="viruses have caused severe and lethal infections in humans"/>
  <result pre="and lethal infections in humans (CDC, 2017). Since the novel" exact="influenza" post="strain is transmitted in the original host bird, the"/>
  <result pre="humans (Shinya et al., 2006). Although the name of the" exact="influenza" post="virus is common to both seasonal influenza and novel"/>
  <result pre="name of the influenza virus is common to both seasonal" exact="influenza" post="and novel influenza, a new subtype of influenza causes"/>
  <result pre="both seasonal influenza and novel influenza, a new subtype of" exact="influenza" post="causes severe influenza in humans because it is a"/>
  <result pre="and novel influenza, a new subtype of influenza causes severe" exact="influenza" post="in humans because it is a completely new subtype"/>
  <result pre="humans have neither a history of infection nor immunity. Seasonal" exact="influenza" post="mainly infects the upper respiratory tract, while novel influenza"/>
  <result pre="Seasonal influenza mainly infects the upper respiratory tract, while novel" exact="influenza" post="causes pneumonia, mainly due to an infection of the"/>
  <result pre="pulmonary epithelium (Shinya et al., 2006). As described above, novel" exact="influenza" post="causes severe diseases, particularly pneumonia, compared to seasonal influenza,"/>
  <result pre="34% (47/137) for A(H7N9) (Li et al., 2014). 4.3 Oseltamivir-resistant" exact="influenza" post="in seasonal influenza Oseltamivir, an NAI, has been the"/>
  <result pre="A(H7N9) (Li et al., 2014). 4.3 Oseltamivir-resistant influenza in seasonal" exact="influenza" post="Oseltamivir, an NAI, has been the treatment of choice"/>
  <result pre="Oseltamivir, an NAI, has been the treatment of choice for" exact="influenza" post="infection. The emergence of a resistant virus (after day"/>
  <result pre="virus (after day 1) was detected in 43/1207 (3.56%) oseltamivir-treated" exact="influenza" post="A-infected patients, with a higher frequency observed in 1-"/>
  <result pre="of 50 (18%) (Kiso et al., 2004) oseltamivir-treated children. Oseltamivir-resistant" exact="influenza" post="appears and becomes dominant during treatment. Another concern is"/>
  <result pre="worldwide. Single-dose baloxavir is superior to the placebo in alleviating" exact="influenza" post="symptoms and to both oseltamivir and placebo in reducing"/>
  <result pre="viral load 1 day after initiation in patients with uncomplicated" exact="influenza" post="(Hayden et al., 2018). The emergence of baloxavir-resistant mutants"/>
  <result pre="in patients without PA/I38T/M-substituted viruses) (Hirotsu et al., 2019). Baloxavir-resistant" exact="influenza" post="viruses cause new human-to-human infections and have the ability"/>
  <result pre="its efficacy from the beginning to the end of an" exact="influenza" post="pandemic without replacement by resistant strains for which the"/>
  <result pre="among anti-influenza virus drugs used to treat pandemics of novel" exact="influenza" post="An influenza pandemic is a global outbreak of a"/>
  <result pre="virus drugs used to treat pandemics of novel influenza An" exact="influenza" post="pandemic is a global outbreak of a novel influenza"/>
  <result pre="An influenza pandemic is a global outbreak of a novel" exact="influenza" post="A virus. Pandemics occur when novel influenza A viruses"/>
  <result pre="of a novel influenza A virus. Pandemics occur when novel" exact="influenza" post="A viruses emerge that are able to infect people"/>
  <result pre="efficient and sustained manner. Two decades have elapsed since an" exact="avian influenza" post="case was reported in Hong Kong in 1997, and"/>
  <result pre="and sustained manner. Two decades have elapsed since an avian" exact="influenza" post="case was reported in Hong Kong in 1997, and"/>
  <result pre="1997, and a decade has elapsed since the most recent" exact="influenza" post="pandemic that occurred in 2009. Sporadic cases of A(H5N1)"/>
  <result pre="that occurred in 2009. Sporadic cases of A(H5N1) and A(H7N9)" exact="influenza" post="infections have been accumulating, and we must prepare for"/>
  <result pre="and we must prepare for these strains or other novel" exact="influenza" post="strains that might progress to an influenza pandemic and"/>
  <result pre="or other novel influenza strains that might progress to an" exact="influenza" post="pandemic and spread globally, such as A(H1N1)pdm09. Influenza pandemics"/>
  <result pre="Favipiravir is significantly more effective in treating mice with severe" exact="influenza" post="infections characterized by a high viral load than oseltamivir"/>
  <result pre="anti-influenza drug has been exploited in treating patients with severe" exact="influenza" post="in combination with oseltamivir in China (Cao, 2018; Wang"/>
  <result pre="viral replication period is 6 days or longer for seasonal" exact="influenza" post="(Lina et al., 2018; Memoli et al., 2014). When"/>
  <result pre="Thus, 10 days of administration may be required for severe" exact="influenza" post="or novel influenza. 4.5 Pandemics of the 20th century"/>
  <result pre="the 20th century According to the WHO (EuroWHO, 2019), &quot;Three" exact="influenza" post="pandemics occurred at intervals of several decades during the"/>
  <result pre="of influenza, it spread quickly throughout the world. Once an" exact="avian influenza" post="outbreak occurs, more people are infected than in the"/>
  <result pre="influenza, it spread quickly throughout the world. Once an avian" exact="influenza" post="outbreak occurs, more people are infected than in the"/>
  <result pre="pathogenicity may be milder, similar to previous pandemics. If an" exact="influenza" post="pandemic causes severe disease, it may cause substantial damage"/>
  <result pre="(Raabe et al., 2017), norovirus (Ruis et al., 2018), and" exact="rabies" post="(Baker, 2017). Notably, as a broad spectrum anti-RNA virus"/>
  <result pre="an emergency or compassionate treatment for Lassa fever, norovirus, and" exact="rabies" post="cases. This review focuses on human administration in terms"/>
  <result pre="fever (Raabe et al., 2017), norovirus (Ruis et al., 2018)," exact="rabies" post="(Baker, 2017), and SFTS (Yasukawa, 2016). Some treatments were"/>
  <result pre="showed accelerated clinical recovery compared to oseltamivir monotherapy in severe" exact="influenza" post="in China (Cao, 2018; Wang et al., 2019). 5.4"/>
  <result pre="Wang et al., 2019). 5.4 The dose of favipiravir for" exact="influenza" post="and Ebola virus infection The antiviral activity (EC50) of"/>
  <result pre="Ebola virus infection The antiviral activity (EC50) of favipiravir against" exact="influenza" post="and Ebola viruses is different from the range of"/>
  <result pre="Tablets 200 mg package insert). The approved favipiravir dose for" exact="influenza" post="in Japan is 1600 mg twice a day on"/>
  <result pre="mg/day on days 1–9. The antiviral concentration of favipiravir in" exact="influenza" post="is achieved in the lung epithelium by diffusion from"/>
  <result pre="2019; Vanderlinden et al., 2016). We observed a transition of" exact="influenza" post="virus and poliovirus in cultures treated with favipiravir but"/>
  <result pre="Favipiravir-4-ribofuranosyl-5′-triphosphate (RTP) has a higher affinity for the RdRp of" exact="influenza" post="virus than GTP and functions as a chain terminator"/>
  <result pre="chain termination at the incorporated site during the elongation of" exact="herpes simplex" post="virus and varicella-zoster virus DNA and prevents viral DNA"/>
  <result pre="its incorporation into the RNA strand and transitions in the" exact="influenza" post="virus genome. The increased rate of transition mutations observed"/>
  <result pre="properties of viral RdRp. 6.4 RNA-dependent RNA polymerase (RdRp) of" exact="influenza" post="virus causes mutations A biased nucleotide pool is a"/>
  <result pre="RNA polymerase and an equivalent or higher fidelity than murine" exact="leukemia" post="virus reverse transcriptase (Aggarwal et al., 2010). The mutation"/>
  <result pre="reverse transcriptase (Aggarwal et al., 2010). The mutation frequency of" exact="influenza" post="RdRp is 7.06 × 10−4 nucleotides in wild-type H3N2"/>
  <result pre="results indicate the low fidelity of the RdRp activity of" exact="influenza" post="lacking proofreading activity. Jurkat cells exposed to 500 μM"/>
  <result pre="to be due to the low fidelity of RdRp of" exact="influenza" post="virus and misincorporation of nucleotides by the biased nucleotide"/>
  <result pre="mutants 7.1 Comparison of the generation of resistant herpesvirus and" exact="influenza" post="virus We have isolated a herpes simplex virus resistant"/>
  <result pre="of resistant herpesvirus and influenza virus We have isolated a" exact="herpes simplex" post="virus resistant to acyclovir, phosphonoacetic acid, and foscarnet, a"/>
  <result pre="baloxavir marboxil (baloxavir)-resistant virus has emerged in patients with seasonal" exact="influenza" post="during treatment, and the isolated virus has been replaced"/>
  <result pre="possibility that a favipiravir-resistant virus appeared in cultured cells while" exact="influenza" post="virus was growing in the presence of favipiravir and"/>
  <result pre="in cultures treated with favipiravir We tried to isolate favipiravir-resistant" exact="influenza" post="virus and poliovirus from 28 and 10 25 cm2"/>
  <result pre="replacement with the resistant virus. Spontaneous mutation rates of the" exact="influenza" post="virus RdRp complex and poliovirus 3D RdRp are both"/>
  <result pre="al., 2014; Drake, 1993; Gubareva &amp;amp; Fry, 2019). Titers of" exact="influenza" post="virus and poliovirus in the culture reach approximately 108"/>
  <result pre="replaced by the favipiravir-resistant mutants. We isolated susceptibility variants of" exact="influenza" post="virus and poliovirus in the cultures treated with favipiravir"/>
  <result pre="of favipiravir-resistant mutants Many laboratories have attempted to isolate favipiravir-resistant" exact="influenza" post="viruses but have not been successful. Recently, mutants of"/>
  <result pre="influenza viruses but have not been successful. Recently, mutants of" exact="influenza" post="virus (Goldhill et al., 2018) and chikungunya virus (Abdelnabi"/>
  <result pre="Recently, mutants of influenza virus (Goldhill et al., 2018) and" exact="chikungunya" post="virus (Abdelnabi et al., 2017; Delang et al., 2014)"/>
  <result pre="mutation in the F1 motif of the RdRp (nsP4) in" exact="chikungunya" post="virus is less susceptible to favipiravir, displays a reduced"/>
  <result pre="et al., 2014). The corresponding K-to-R substitution (K159R) of the" exact="chikungunya" post="virus K291R mutation was introduced in the coxsackievirus B3"/>
  <result pre="et al., 2014; Goldhill et al., 2019). Favipiravir-resistant mutants of" exact="influenza" post="virus have been created by reverse-engineering and replicate as"/>
  <result pre="has been observed in many laboratories. Two highly pathogenic A(H5N1)" exact="influenza" post="viruses from chicken and Muscovy duck and one H3"/>
  <result pre="influenza viruses from chicken and Muscovy duck and one H3" exact="influenza" post="virus from ruddy turnstone and two swine (H1N1) origin"/>
  <result pre="influenza virus from ruddy turnstone and two swine (H1N1) origin" exact="influenza" post="viruses possess the PB1-V43I mutation that may result in"/>
  <result pre="changes in the susceptibility to favipiravir when these types of" exact="influenza" post="viruses cause a pandemic. 7.4 A favipiravir-resistant virus has"/>
  <result pre="clinical trials Antiviral susceptibility was examined in 57 pairs of" exact="influenza" post="viruses isolated from patients before and after the administration"/>
  <result pre="or baloxavir resistance might be observed in clinical trials of" exact="influenza" post="treatment with oseltamivir and baloxavir with a similar number"/>
  <result pre="be maintained from the beginning to the end of the" exact="influenza" post="pandemic and that all patients could be treated effectively."/>
  <result pre="death from severe infections may be liver failure, renal failure," exact="respiratory failure" post="and encephalitis. Ebola virus infection seemed to be difficult"/>
  <result pre="before losing the recoverable function of the target organ. Since" exact="pneumonia" post="is the main cause of death by influenza, it"/>
  <result pre="of treatment. Time from illness onset to oseltamivir treatment in" exact="avian influenza" post="A(H7N9) virus infection is 6 days (5–9 days), and"/>
  <result pre="treatment. Time from illness onset to oseltamivir treatment in avian" exact="influenza" post="A(H7N9) virus infection is 6 days (5–9 days), and"/>
  <result pre="days), and time from illness onset to the development of" exact="acute respiratory distress syndrome" post="(ARDS) is 7 days (5–9 days) (Li et al.,"/>
  <result pre="million people has been performed as a countermeasure against novel" exact="influenza" post="in Japan. Favipiravir has been used to treat lethal"/>
  <result pre="of implementation (Kuhar et al., 2013). Since children died of" exact="avian influenza" post="A(H5N1) in Hong Kong in 1997 (Ku &amp;amp; Chan,"/>
  <result pre="implementation (Kuhar et al., 2013). Since children died of avian" exact="influenza" post="A(H5N1) in Hong Kong in 1997 (Ku &amp;amp; Chan,"/>
  <result pre="(Ku &amp;amp; Chan, 1999), concern has been expressed about novel" exact="influenza" post="pandemics, such as A(H5N1) and A(H7N9). An influenza pandemic"/>
  <result pre="about novel influenza pandemics, such as A(H5N1) and A(H7N9). An" exact="influenza" post="pandemic consisting of a global outbreak of influenza A(H1N1)pdm09"/>
  <result pre="A(H7N9). An influenza pandemic consisting of a global outbreak of" exact="influenza" post="A(H1N1)pdm09 virus occurred in 2009, and although the pathogenicity"/>
  <result pre="a pandemic and health problems. Although there was immunity against" exact="influenza" post="A(H1N1)pdm09 among the elderly, it caused health problems for"/>
  <result pre="social impact. As a next candidate for a pandemic influenza," exact="avian influenza," post="such as A(H5N1) or A(H7N9), causes a severe infection"/>
  <result pre="such as A(H5N1) or A(H7N9), causes a severe infection and" exact="pneumonia" post="due to the prolonged viral replication caused by the"/>
  <result pre="to be to stockpile vaccines and anti-influenza drugs for novel" exact="influenza" post="strains to cope with pandemics. The specific features and"/>
  <result pre="role among anti-influenza drugs in the treatment of a lethal" exact="influenza" post="pandemic. This review helps clinicians, scientists, and policy-makers considering"/>
  <result pre="helps clinicians, scientists, and policy-makers considering preparedness strategies for an" exact="avian influenza" post="pandemic, such as the use of the anti-influenza drug"/>
  <result pre="clinicians, scientists, and policy-makers considering preparedness strategies for an avian" exact="influenza" post="pandemic, such as the use of the anti-influenza drug"/>
  <result pre="sent to the institution. References References AbdelnabiR.JochmansD.VerbekenE.NeytsJ.DelangL.Antiviral treatment efficiently inhibits" exact="chikungunya" post="virus infection in the joints of mice during the"/>
  <result pre="viral polymeraseJournal of Virology912017(e00487–17) AggarwalS.Bradel-TrethewayB.TakimotoT.DewhurstS.KimB.Biochemical characterization of enzyme fidelity of" exact="influenza" post="A virus RNA polymerase complexPLoS One52010e10372 AkahoshiY.KandaJ.OhnoA.KomiyaY.GomyoA.HayakawaJ. …KandaY.Acyclovir-resistant herpes"/>
  <result pre="of influenza A virus RNA polymerase complexPLoS One52010e10372 AkahoshiY.KandaJ.OhnoA.KomiyaY.GomyoA.HayakawaJ. …KandaY.Acyclovir-resistant" exact="herpes simplex" post="virus 1 infection early after allogeneic hematopoietic stem cell"/>
  <result pre="patients treated with Favipiravir (T-705)-Sierra Leone, 2014Clinical Infectious Diseases6320161288129427553371 BakerL.Bat" exact="rabies" post="outbreak in Peru claims one, but others survive: Mass"/>
  <result pre="Mass vaccination campaign underwayhttps://rabiesalliance.org/resource/bat-rabies-outbreak-peru-claims-one-others-survive-mass-vaccination-campaign-underway2017 BaranovichT.WongS.S.ArmstrongJ.MarjukiH.WebbyR.J.WebsterR.G.GovorkovaE.A.T-705 (favipiravir) induces lethal mutagenesis in" exact="influenza" post="A H1N1 viruses in vitroJournal of Virology8720133741375123325689 BatiukT.D.Schnizlein-BickC.PlotkinZ.DagherP.C.Guanine nucleosides"/>
  <result pre="and Respiratory Diseases (NCIRD)https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm CheungP.P.WatsonS.J.ChoyK.T.Fun SiaS.WongD.D.PoonL.L. …YenH.L.Generation and characterization of" exact="influenza" post="A viruses with altered polymerase fidelityNature Communications520144794 CraigS.P.3rdEakinA.E.Purine phosphoribosyltransferasesThe"/>
  <result pre="of Microbiology, Immunology, and Infection512017581586 DaikokuT.TannaiH.HondaM.OnoeT.MatsuoK.OnoyeY. …ShirakiK.Subclinical generation of acyclovir-resistant" exact="herpes simplex" post="virus with mutation of homopolymeric guanosine strings during acyclovir"/>
  <result pre="acyclovir therapyJournal of Dermatological Science82201616016526917345 DaikokuT.YoshidaY.OkudaT.ShirakiK.Characterization of susceptibility variants of" exact="influenza" post="virus grown in the presence of T-705Journal of Pharmacological"/>
  <result pre="regulation of lung inflammation and immunopathology by TNF-alpha during acute" exact="influenza" post="infectionThe American Journal of Pathology17920112963297622001698 DelangL.AbdelnabiR.NeytsJ.Favipiravir as a potential"/>
  <result pre="and emerging RNA virusesAntiviral Research1532018859429524445 DelangL.Segura GuerreroN.TasA.QueratG.PastorinoB.FroeyenM. …LeyssenP.Mutations in the" exact="chikungunya" post="virus non-structural proteins cause resistance to favipiravir (T-705), a"/>
  <result pre="broad-spectrum antiviralThe Journal of Antimicrobial Chemotherapy6920142770278424951535 DharanN.J.GubarevaL.V.MeyerJ.J.Okomo-AdhiamboM.McClintonR.C.MarshallS.A. …FryA.M.Infections with oseltamivir-resistant" exact="influenza" post="A(H1N1) virus in the United StatesJAMA30120091034104119255110 DieboldS.S.MontoyaM.UngerH.AlexopoulouL.RoyP.HaswellL.E. …Reis e"/>
  <result pre="into high interferon producersNature424200332432812819664 DoyleW.J.SkonerD.P.HaydenF.BuchmanC.A.SerokyJ.T.FiremanP.Nasal and otologic effects of experimental" exact="influenza" post="A virus infectionThe Annals of Otology, Rhinology, and Laryngology10319945969"/>
  <result pre="Agents and Chemotherapy46200297798111897578 FurutaY.TakahashiK.Kuno-MaekawaM.SangawaH.UeharaS.KozakiK. …ShirakiK.Mechanism of action of T-705 against" exact="influenza" post="virusAntimicrobial Agents and Chemotherapy49200598198615728892 FurutaY.TakahashiK.ShirakiK.SakamotoK.SmeeD.F.BarnardD.L. …MorreyJ.D.T-705 (favipiravir) and related"/>
  <result pre="infectionsAntiviral Research8220099510219428599 GoldhillD.H.LangatP.XieH.GalianoM.MiahS.KellamP. …BarclayW.S.Determining the mutation Bias of Favipiravir in" exact="influenza" post="virus using next-generation sequencingJournal of Virology932019e01217e0121830381482 GoldhillD.H.Te VelthuisA.J.W.FletcherR.A.LangatP.ZambonM.LackenbyA.BarclayW.S.The mechanism"/>
  <result pre="feverPLoS Neglected Tropical Diseases72013e2614 GowenB.B.WestoverJ.B.MiaoJ.Van WettereA.J.RigasJ.D.HickersonB.T. …WangZ.Modeling severe fever with" exact="thrombocytopenia" post="syndrome virus infection in Golden Syrian hamsters: Importance of"/>
  <result pre="immune response of lung epithelial cells to double-stranded RNA and" exact="influenza" post="A virusThe Journal of Biological Chemistry28020055571558015579900 HamaY.KurokawaM.ImakitaM.YoshidaY.ShimizuT.WatanabeW.ShirakiK.Interleukin 12 is"/>
  <result pre="Biological Chemistry28020055571558015579900 HamaY.KurokawaM.ImakitaM.YoshidaY.ShimizuT.WatanabeW.ShirakiK.Interleukin 12 is a primary cytokine responding to" exact="influenza" post="virus infection in the respiratory tract of miceActa Virologica53200923324019941386"/>
  <result pre="miceAntiviral Research1572018182629936152 HaydenF.G.SugayaN.HirotsuN.LeeN.de JongM.D.HurtA.C. …Baloxavir Marboxil InvestigatorsG.Baloxavir Marboxil for uncomplicated" exact="influenza" post="in adults and adolescentsThe New England Journal of Medicine379201891392330184455"/>
  <result pre="outcomesClin Infect Dis.2019ciz90810.1093/cid/ciz90831538644 HurtA.C.ErnestJ.DengY.M.IannelloP.BesselaarT.G.BirchC. …BarrI.G.Emergence and spread of oseltamivir-resistant A(H1N1)" exact="influenza" post="viruses in Oceania, South East Asia and South AfricaAntiviral"/>
  <result pre="and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards" exact="influenza" post="A virus polymerasePLoS One82013e68347 JochmansD.van NieuwkoopS.SmitsS.L.NeytsJ.FouchierR.A.van den HoogenB.G.Antiviral activity"/>
  <result pre="and Chemotherapy6020164620462927185803 JulanderJ.G.ShaferK.SmeeD.F.MorreyJ.D.FurutaY.Activity of T-705 in a hamster model of" exact="yellow fever" post="virus infection in comparison with that of a chemically"/>
  <result pre="compound, T-1106Antimicrobial Agents and Chemotherapy53200920220918955536 JulanderJ.G.SmeeD.F.MorreyJ.D.FurutaY.Effect of T-705 treatment on" exact="western equine encephalitis" post="in a mouse modelAntiviral Research82200916917119428608 KamiyamaT.KurokawaM.ShirakiK.Characterization of the DNA"/>
  <result pre="Agents and Chemotherapy53200920220918955536 JulanderJ.G.SmeeD.F.MorreyJ.D.FurutaY.Effect of T-705 treatment on western equine" exact="encephalitis" post="in a mouse modelAntiviral Research82200916917119428608 KamiyamaT.KurokawaM.ShirakiK.Characterization of the DNA"/>
  <result pre="viruses resistant to acyclovirThe Journal of General Virology8220012761276511602787 KisoM.MitamuraK.Sakai-TagawaY.ShiraishiK.KawakamiC.KimuraK. …KawaokaY.Resistant" exact="influenza" post="A viruses in children treated with oseltamivir: Descriptive studyLancet364200475976515337401"/>
  <result pre="oseltamivir: Descriptive studyLancet364200475976515337401 KisoM.TakahashiK.Sakai-TagawaY.ShinyaK.SakabeS.LeQ.M. …KawaokaY.T-705 (favipiravir) activity against lethal H5N1" exact="influenza" post="A virusesProceedings of the National Academy of Sciences of"/>
  <result pre="the United States of America107201088288720080770 KuA.S.ChanL.T.The first case of H5N1" exact="avian influenza" post="infection in a human with complications of adult respiratory"/>
  <result pre="United States of America107201088288720080770 KuA.S.ChanL.T.The first case of H5N1 avian" exact="influenza" post="infection in a human with complications of adult respiratory"/>
  <result pre="of Pharmacology474200328329312921875 KurokawaM.ImakitaM.KumedaC.A.ShirakiK.Cascade of fever production in mice infected with" exact="influenza" post="virusJournal of Medical Virology5019961521588915881 KurokawaM.ImakitaM.KumedaC.A.YukawaT.A.ShirakiK.Kakkon-to suppressed interleukin 1α production"/>
  <result pre="KurokawaM.ImakitaM.KumedaC.A.YukawaT.A.ShirakiK.Kakkon-to suppressed interleukin 1α production responsive to interferon and alleviated" exact="influenza" post="infection in miceJ Traditional Med131996201209 KurokawaM.KumedaC.A.YamamuraJ.KamiyamaT.ShirakiK.Antipyretic activity of cinnamyl"/>
  <result pre="Med131996201209 KurokawaM.KumedaC.A.YamamuraJ.KamiyamaT.ShirakiK.Antipyretic activity of cinnamyl derivatives and related compounds in" exact="influenza" post="virus-infected miceEuropean Journal of Pharmacology348199845519650830 KurokawaM.TsuritaM.BrownJ.FukudaY.ShirakiK.Effect of interleukin-12 level"/>
  <result pre="by Kakkon-to, a herbal medicine, on the early stage of" exact="influenza" post="infection in miceAntiviral Research56200218318812367723 KurokawaM.WatanabeW.ShimizuT.SawamuraR.ShirakiK.Modulation of cytokine production by"/>
  <result pre="cytokine production by 7-hydroxycoumarin in vitro and its efficacy against" exact="influenza" post="infection in miceAntiviral Research85201037338019913056 KurokawaM.YamamuraJ.LiZ.SatoH.HitomiN.TatsumiY.ShirakiK.Antipyretic activity of gingyo-san, a"/>
  <result pre="miceAntiviral Research85201037338019913056 KurokawaM.YamamuraJ.LiZ.SatoH.HitomiN.TatsumiY.ShirakiK.Antipyretic activity of gingyo-san, a traditional medicine, in" exact="influenza" post="virus-infected miceChem Pharm Bull (Tokyo)461998144414479775439 KurosakiK.MiwaN.YoshidaY.KurokawaM.KurimotoM.EndoS.ShirakiK.Therapeutic basis of vidarabine"/>
  <result pre="adenovirus-induced haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. …YuH.Global epidemiology of" exact="avian influenza" post="A H5N1 virus infection in humans, 1997-2015: A systematic"/>
  <result pre="haemorrhagic cystitisAntiviral Chemistry &amp;amp; Chemotherapy15200428128515535050 LaiS.QinY.CowlingB.J.RenX.WardropN.A.GilbertM. …YuH.Global epidemiology of avian" exact="influenza" post="A H5N1 virus infection in humans, 1997-2015: A systematic"/>
  <result pre="of individual case dataThe Lancet Infectious Diseases162016e108e11827211899 LeeK.KolbA.W.SverchkovY.CuellarJ.A.CravenM.BrandtC.R.Recombination analysis of" exact="herpes simplex" post="virus 1 reveals a Bias toward GC content and"/>
  <result pre="repeat regionsJournal of Virology8920157214722325926637 LiQ.ZhouL.ZhouM.ChenZ.LiF.WuH. …FengZ.Epidemiology of human infections with" exact="avian influenza" post="A(H7N9) virus in ChinaThe New England Journal of Medicine370201452053223614499"/>
  <result pre="regionsJournal of Virology8920157214722325926637 LiQ.ZhouL.ZhouM.ChenZ.LiF.WuH. …FengZ.Epidemiology of human infections with avian" exact="influenza" post="A(H7N9) virus in ChinaThe New England Journal of Medicine370201452053223614499"/>
  <result pre="monitoring for the emergence of oseltamivir resistance in patients with" exact="influenza" post="A infections in the influenza resistance information studyInfluenza and"/>
  <result pre="oseltamivir resistance in patients with influenza A infections in the" exact="influenza" post="resistance information studyInfluenza and Other Respiratory Viruses12201826727829265727 MaurerJ.R.FrostA.E.EstenneM.HigenbottamT.GlanvilleA.R.International guidelines"/>
  <result pre="mammalian and avian herpesvirusesJournal of Virology742000104011040611044084 MeijerA.LackenbyA.HungnesO.LinaB.van der WerfS.SchweigerB. …ZambonM.Oseltamivir-resistant" exact="influenza" post="virus A (H1N1), Europe, 2007-08 seasonEmerging Infectious Diseases15200955256019331731 MemoliM.J.AthotaR.ReedS.CzajkowskiL.BristolT.ProudfootK."/>
  <result pre="Europe, 2007-08 seasonEmerging Infectious Diseases15200955256019331731 MemoliM.J.AthotaR.ReedS.CzajkowskiL.BristolT.ProudfootK. …TaubenbergerJ.K.The natural history of" exact="influenza" post="infection in the severely immunocompromised vs nonimmunocompromised hostsClinical Infectious"/>
  <result pre="for Crimean-Congo hemorrhagic feverPLoS Neglected Tropical Diseases82014e2804 OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM. …CusackS.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
  <result pre="…SpetzA.L.A single-stranded oligonucleotide inhibits toll-like receptor 3 activation and reduces" exact="influenza" post="A (H1N1) infectionFrontiers in Immunology102019216131572376 RaabeV.N.KannG.RibnerB.S.MoralesA.VarkeyJ.B.MehtaA.K. …Emory Serious Communicable"/>
  <result pre="onsetScientific Reports520151477526456301 SangawaH.KomenoT.NishikawaH.YoshidaA.TakahashiK.NomuraN.FurutaY.Mechanism of action of T-705 ribosyl triphosphate against" exact="influenza" post="virus RNA polymeraseAntimicrobial Agents and Chemotherapy5720135202520823917318 SchartonD.BaileyK.W.VestZ.WestoverJ.B.KumakiY.Van WettereA. …GowenB.B.Favipiravir"/>
  <result pre="with ribavirin treatmentAntiviral Research1042014849224486952 ShimadaY.SuzukiM.ShirasakiF.SaitoE.SogoK.HasegawaM. …ShirakiK.Genital herpes due to acyclovir-sensitive" exact="herpes simplex" post="virus caused secondary and recurrent herpetic whitlows due to"/>
  <result pre="Virology66Pt 219852212292981965 SidwellR.W.BarnardD.L.DayC.W.SmeeD.F.BaileyK.W.WongM.H. …FurutaY.Efficacy of orally administered T-705 on lethal" exact="avian influenza" post="A (H5N1) virus infections in miceAntimicrobial Agents and Chemotherapy51200784585117194832"/>
  <result pre="219852212292981965 SidwellR.W.BarnardD.L.DayC.W.SmeeD.F.BaileyK.W.WongM.H. …FurutaY.Efficacy of orally administered T-705 on lethal avian" exact="influenza" post="A (H5N1) virus infections in miceAntimicrobial Agents and Chemotherapy51200784585117194832"/>
  <result pre="vitro and in vivo activities of T-705 and oseltamivir against" exact="influenza" post="virusAntiviral Chemistry &amp;amp; Chemotherapy14200323524114694986 TakashitaE.EjimaM.OgawaR.FujisakiS.NeumannG.FurutaY. …OdagiriT.Antiviral susceptibility of influenza"/>
  <result pre="against influenza virusAntiviral Chemistry &amp;amp; Chemotherapy14200323524114694986 TakashitaE.EjimaM.OgawaR.FujisakiS.NeumannG.FurutaY. …OdagiriT.Antiviral susceptibility of" exact="influenza" post="viruses isolated from patients pre- and post-administration of favipiravirAntiviral"/>
  <result pre="pre- and post-administration of favipiravirAntiviral Research132201617017727321665 TakashitaE.IchikawaM.MoritaH.OgawaR.FujisakiS.ShirakuraM. …OdagiriT.Human-to-human transmission of" exact="influenza" post="A(H3N2) virus with reduced susceptibility to Baloxavir, Japan, February"/>
  <result pre="(Favipiravir) suppresses tumor necrosis factor alpha production in response to" exact="influenza" post="virus infection: A beneficial feature of T-705 as an"/>
  <result pre="in the treatment of infections with lethal severe fever with" exact="thrombocytopenia" post="syndrome virusmSphere112016Jan-Feb. e00061–15 TsuritaM.KurokawaM.ImakitaM.FukudaY.WatanabeY.ShirakiK.Early augmentation of interleukin (IL)-12 level"/>
  <result pre="with clarithromycin or intranasally with IL-12 results in alleviation of" exact="influenza" post="infectionThe Journal of Pharmacology and Experimental Therapeutics298200136236811408563 UeharaT.HaydenF.G.KawaguchiK.OmotoS.HurtA.C.De JongM.D."/>
  <result pre="Journal of Pharmacology and Experimental Therapeutics298200136236811408563 UeharaT.HaydenF.G.KawaguchiK.OmotoS.HurtA.C.De JongM.D. …KidaH.(2019). Treatment-emergent" exact="influenza" post="variant viruses with reduced Baloxavir susceptibility: Impact on clinical"/>
  <result pre="VanderlindenE.VranckenB.Van HoudtJ.RajwanshiV.K.GillemotS.AndreiG. …NaesensL.Distinct effects of T-705 (Favipiravir) and ribavirin on" exact="influenza" post="virus replication and viral RNA synthesisAntimicrobial Agents and Chemotherapy6020166679669127572398"/>
  <result pre="oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with" exact="influenza" post="virus infectionJ Infect Dis2019jiz65610.1093/infdis/jiz65631822885 WestoverJ.B.SefingE.J.BaileyK.W.Van WettereA.J.JungK.H.DagleyA. …GowenB.B.Low-dose ribavirin potentiates"/>
  <result pre="in Escherichia coliDNA Repair (Amst)420051450145616207537 WhitleyR.J.HaydenF.G.ReisingerK.S.YoungN.DutkowskiR.IpeD. …WardP.Oral oseltamivir treatment of" exact="influenza" post="in childrenThe Pediatric Infectious Disease Journal20200112713311224828 WongJ.P.ChristopherM.E.ViswanathanS.KarpoffN.DaiX.DasD. …SalazarA.M.Activation of"/>
  <result pre="WongJ.P.ChristopherM.E.ViswanathanS.KarpoffN.DaiX.DasD. …SalazarA.M.Activation of toll-like receptor signaling pathway for protection against" exact="influenza" post="virus infectionVaccine2720093481348319200852 YamadaK.NoguchiK.KomenoT.FurutaY.NishizonoA.Efficacy of Favipiravir (T-705) in rabies Postexposure"/>
  <result pre="protection against influenza virus infectionVaccine2720093481348319200852 YamadaK.NoguchiK.KomenoT.FurutaY.NishizonoA.Efficacy of Favipiravir (T-705) in" exact="rabies" post="Postexposure prophylaxisThe Journal of Infectious Diseases21320151253126126655300 YangC.W.ChenS.M.A comparative study"/>
  <result pre="comparative study of human TLR 7/8 stimulatory trimer compositions in" exact="influenza" post="A viral genomesPLoS One72012e30751 YasukawaM.Clinical study of favipiravir for"/>
  <result pre="YasukawaM.Clinical study of favipiravir for patients with severe fever with" exact="thrombocytopenia" post="syndromeIn UMIN000022398https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R0000331942016 ZhuW.ZhangZ.HeS.WongG.BanadygaL.QiuX.Successful treatment of Marburg virus with orally"/>
 </snippets>
</snippetsTree>
